IFN-κ, a novel type i IFN, is undetectable in HPV-positive human cervical keratinocytes

Laboratory Investigation

Volumn 90, Issue 10, 2010, Pages 1482-1491

  Decarlo, Correne A ^a,g   Severini, Alberto ^b   Edler, Lutz ^c   Escott, Nicholas G ^d   Lambert, Paul F ^e   Ulanova, Marina ^f   Zehbe, Ingeborg ^a  

^a Thunder Bay Regional Research Institute   (Canada)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d THUNDER BAY REGIONAL HEALTH SCIENCES CENTRE   (Canada)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^g UNIVERSITY OF VICTORIA   (Canada)

Author keywords

cervical tissue; human papillomavirus; interferon ; laser capture microdissection; quantitative real time polymerase chain reaction

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; INTERFERON; INTERFERON KAPPA; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DOWN REGULATION; EX VIVO STUDY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX DISEASE; WART VIRUS;

CERVIX UTERI; DOWN-REGULATION; FEMALE; HUMANS; INTERFERON TYPE I; INTERFERON-BETA; INTERFERON-GAMMA; KERATINOCYTES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UTERINE CERVICAL NEOPLASMS;

EID: 77957274057     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.95     Document Type: Article

References (42)

1. Polman CH, O'Conner PW, Havrdova E, et al. A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-933. (Pubitemid 43313657)
2. De Maeyer E, De Maeyer-Guignard J. Interferons. In: Thompson A (ed.) The Cytokine Handbook, 3rd edn., Academic Press: San Diego, CA, USA, pp 491-516.
3. Gerein V, Rastorguev E, Gerein J, et al. Use of interferon-alpa in recurrent repiratory papillomatosis: 20 year follow-up. Ann Otol Rhinol Laryngol 2005;114:463-471.
4. Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatment of genital warts. Dermatol Outline J 2006;12:5.
5. Isaacs A, Lindenman J. Virus interference I. The interferon. Proc R Soc 1957;147:258-267.
6. Takaoka A, Hayakawa S, Yani H, et al. Integration of interferon-a/b signalling to p53 responses in tumor suppression and antiviral defence. Nature 2003;424:516-523. (Pubitemid 36975769)
7. Stetson DB, Medzhitov R. Type I interferons and host defense. Immunity 2006;25:373-381.
8. Pestka S, Langer JA, Zoon KC, et al. Interferons and their actions. Annu Rev Biochem 1987;56:727-777. (Pubitemid 17105465)
9. Bach EA, Aguet M, Schreiber RD, et al. The IFN receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997;15:563-591. (Pubitemid 27169292)
10. Lafleur DW, Nardelli B, Tsareva T, et al. Interferon-k, a novel type I interferon expressed in human keratinocytes. J Biol Chem 2001;276:39765-39771. (Pubitemid 37391383)
11. Buontempo PJ, Jubin RG, Buontempo CA, et al. Antiviral activity of transiently expressed IFN-k is cell-associated. J Inter Cyto Res 2006;52:40-52.
12. Manns MP, McHutchison JG, Gordon SC, et al. Albrecht Interferon alfa-2b plus ribavirin compared with interferon alfa2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965. (Pubitemid 32913521)
13. Scarponi C, Nardelli B, LaFleur DW, et al. Analysis of IFN-k expression in pathological skin conditions: downregulation in psoriasis and atopic dermatitis. J Inter Cyto Res 2006;26:133-140.
14. Park JS, Kim EJ, Kwon HJ, et al. Inactivation of interferon regulator factor-1 tumor suppressor protein by HPV E7 oncoprotein. J Biol Chem 2000;275:6764-6769.
15. Ronco LV, Karpova AY, Vidal M, et al. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998;12:2061-2072. (Pubitemid 28323879)
16. Barnard P, McMillan NA. The human papillomavirus E7 oncoprotein abrogates signalling mediated by interferon-alpha. Virology 1999;259:305-313. (Pubitemid 29393381)
17. Li S, Labrecque S, Gauzzi MC, et al. The human papilloma vrus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-a. Oncogene 1999;18:5727-5737. (Pubitemid 29507426)
18. Chang YE, Laimins LA. Microarray analysis identifies interferoninducible genes and stat-1 as major transcriptional targets of human papillomavrus type 31. J Virol 2000;74:4174-4182.
19. Nees M, Geoghegan JM, Hyman T, et al. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kB-responsive genes in cervical keratinocytes. J Virol 2001;75:4283-4296. (Pubitemid 32410141)
20. Bachmann A, Hanke B, Zawatzky R, et al. Disturbance of tumor necrosis factor alpha-mediated beta interferon signalling in cervical carcinoma cells. J Virol 2002;76:280-291. (Pubitemid 33139013)
21. de Gruijl TD, Bontkes HJ, van den Muysenberg AJ, et al. Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix. Eur J Cancer 1999;35:490-497.
22. Gey A, Kumari P, Sambandam A, et al. Identification and characterisation of a group of cervical carcinoma patients with profound downregulation of intratumoral type I (IFN-g) and type 2 (IL-4) cytokine mRNA expression. Eur J Cancer 2003;39:595-603. (Pubitemid 36287371)
23. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-361.
24. Goleski VA, Dawood M, Smart G, , et al., The Canadian Women's HIV Study Group. A microsphere based multiplexed assay for genotyping 46 mucosal human papillomavirus types. Proceedings from the Canadian Association for Clinical Microbiology and Infectious Diseases Annual Conference, 14-18 March 2007; Halifax Canada.
25. Goleski VA, Dawood M, Ratnam S, et al. Luminex-based assay for multiplex genotyping of 45 mucosal human papillomavirus types. Proceedings from the European Research Organisation on Genital Infection and Neoplasia Conference, 12-15 November 2008; Nice France.
26. Zehbe I, Rylander E, Edlund K, et al. Detection of human papillomavirus in cervical intra-epithelial neoplasia, using in situ hybridization and various polymerase chain reaction techniques. Virchows Arch 1996;428:151-157. (Pubitemid 26237445)
27. Culling CFA, Allison RT, Barr WT. Cellular pathology techniques. In: Culling CFA, Allison RT, Barr WT (eds). Microorganisms, 4th edn. Butterworths: London, PA, 1985, pp 55-59.
28. Allen-Hoffmann BL, Schlosser SJ, Ivarie CA, et al. Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. J Invest Dermatol 2000;114: 444-455. (Pubitemid 30415329)
29. Zehbe I, Richard C, DeCarlo CA, et al. Human papillomavirus 16 E6 variants in their dysregulation of human keratinocyte differentiation and apoptosis. Virol 2009;383:69-77.
30. Flores ER, Allen-Hoffmann BL, Lee D, et al. The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J Virol 2000;74:6622-6631. (Pubitemid 30429831)
31. DeCarlo CA, Escott NG, Werner J, et al. Gene expression analysis of interferon kappa in laser capture microdissected cervical epithelium. Anal Biochem 2008;381:59-66.
32. Fleiss JL, Levin B, Cho Paik M. Statistical Methods for Rates and Proportions. John Wiley & Sons: New Jersey, USA, 2003.
33. Hollander M, Wolfe DA. Nonparametric Statistical Methods. John Wiley & Sons: New Jersey, USA, 1999.
34. DellOste V, Azzimonti B, Mondini M, et al. Altered expression of UVBinduced cytokines in human papillomavirus-immortalized epithelial cells. J Gen Virol 2008;89:2461-2466.
35. Woodworth CD. HPV innate immunity. Front Biosci 2002;7: d2058-d2071.
36. Richard C, Lanner C, Naryzhny SN, et al. The immortalizing and transforming ability of two common human papillomavirus 16 E6 variants with different prevalences in cervical cancer. Oncogene 2010, doi:10.1038/onc.2010.93 (in press).
37. Rincon-Orozco B, Halec G, Rosenberger S, et al. Epigenetic silencing of interferon-k in human papillomavirus type 16-positive cells. Cancer Res 2009;69:8718-8725.
38. Gessani S, Belardelli F, Pecorelli A, et al. Bacterial lipopolysaccharide and gamma interferon induce transcription of beta interferon mRNA and interferon secretion in murine macrophages. J Virol 1989;63: 2785-2789. (Pubitemid 19137558)
39. Nardelli B, Zaritskaya L, Semenuk M, et al. Regulatory effect of IFN-k, a novel type I IFN, on cytokine production by cells of the innate immune system. J Immunol 2002;169:4822-4830. (Pubitemid 35217145)
40. Vassileva G, Chen SC, Zeng M, et al. Expression of a novel murine type I IFN in the pancreatic islets induces diabetes in mice. J Immunol 2003;170:5748-5755. (Pubitemid 36617868)
41. El-Sherif AM, Seth R, Tighe PJ, et al. Quantitative analysis of IL-10 and IFN-gamma mRNA levels in normal cervix and human papillomavirus type16 associated cervical precancer. J Path 2001;195:179-185. (Pubitemid 32899026)
42. Clerici M, Merola M, Ferrario E, et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Nat Cancer Inst 1997; 89:245-250. (Pubitemid 27073762)